News and Press Releases
VALO THERAPEUTICS APPOINTS MICHAEL STEIN AS CHIEF EXECUTIVE OFFICER
Seasoned Healthcare Entrepreneur strengthens Management Team
DNAtrix and Valo Therapeutics Enter into Strategic Partnership to Develop Peptide-Coated Oncolytic Viruses for Treating Cancer
HOUSTON and HELSINKI, Nov. 13, 2018 -- DNAtrix and Valo Therapeutics today announced an exclusive R&D collaboration to develop enhanced vaccines using DNAtrix's clinical stage viruses and Valo's proprietary antigenic peptide technology. DNAtrix's clinical stage oncolytic adenovirus platform and Valo's PeptiCRAd (Peptide-coated Conditionally Replicating Adenovirus) vaccination technology will be combined to generate a novel "armed oncolytic vaccine" for cancer therapy. While oncolytic adenoviruses alone offer a promising strategy to treat cancer, in combination with PeptiCRAd, superior and durable immunological protection
Valo Therapeutics receives $4.6 million non-dilutive funding from Tekes, in order to accelerate development of a novel oncolytic virus-based cancer immunotherapy
Helsinki, Finland, July 4, 2017. The Finnish Funding Agency for Innovation, Tekes, has granted Valo Therapeutics a $4.6 million non-dilutive loan for the preparation of a Phase I trial of a novel oncolytic virus-based cancer immunotherapy called PeptiCRAd. Valo Therapeutics has now raised $8 million (including $3.4m seed capital in January 2017) towards its mission to provide cancer patients with less toxic and longer lasting therapeutic options. Valo Therapeutics aims at combining the PeptiCRAd technology with check point inhibitors in
Valo Therapeutics closes seed fundraising round to develop a novel oncolytic virus-based cancer immunotherapy
A spin-out from the University of Helsinki, Valo Therapeutics is developing novel oncolytic viral vaccines for the treatment of multiple forms of cancer.
Valo Therapeutics päätti siemenrahoituskierroksen kehittääkseen uutta onkolyyttiseen virukseen perustuvaa syövän immunoterapiaa
Valo Therapeutics, spin-out -yhtiö Helsingin yliopistosta, kehittää uutta onkolyyttiseen virukseen perustuvaa syövän immunoterapiaa, jolla voidaan hoitaa useita eri syöpätyyppejä.